Anti-vascular endothelial growth factor for neovascular age-related macular degeneration

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 8, 2014, Pages

  Solomon, Sharon D ^a   Lindsley, Kristina ^b   Vedula, Satyanarayana S ^c   Krzystolik, Magdalena G ^d   Hawkins, Barbara S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d Southern New England Retina Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN ANTIBODY; ANGIOGENESIS INHIBITOR; APTAMER; MONOCLONAL ANTIBODY; PORPHYRIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN; VERTEPORFIN;

BEST CORRECTED VISUAL ACUITY; CENTRAL RETINAL THICKNESS; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; COMPARATIVE EFFECTIVENESS; CONTRAST SENSITIVITY; CORNEA NEOVASCULARIZATION; COST BENEFIT ANALYSIS; DRUG EFFECT; DRUG EFFICACY; ENDOPHTHALMITIS; EYE INFLAMMATION; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); READING SPEED; REVIEW; SYSTEMATIC REVIEW; UVEITIS; VISION; VISUAL ACUITY; VISUAL IMPAIRMENT; VITREOUS HEMORRHAGE; WET MACULAR DEGENERATION; AGED; DRUG ANTAGONISM; INTRAVITREAL DRUG ADMINISTRATION; META ANALYSIS; MIDDLE AGED; RETINA MACULA DEGENERATION; SUBRETINAL NEOVASCULARIZATION;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; APTAMERS, NUCLEOTIDE; CHOROIDAL NEOVASCULARIZATION; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MIDDLE AGED; PORPHYRINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84907190920     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005139.pub3     Document Type: Review

References (255)

1. Keane PA, Heussen FM, Ouyang Y, Mokwa N, Walsh AC, Tufail A, et al.Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age-related macular degeneration. Investigative Ophthalmology and Visual Science 2012;53(3):1152-61.
2. Patel PJ, Chen FK, Cruz L, Rubin GS, Tufail A. Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age-related macular degeneration. Investigative Ophthalmology and Visual Science 2011;52(6):3089-93.
3. Patel PJ, Henderson L, Sivaprasad S, Bunce C, Wormald R, Tufail A. The ABC trial - a randomized double-masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age-related macular degeneration (AMD). Investigative Ophthalmology and Visual Science 2007;48:ARVO E-abstract 4536.
4. Patel PJ, Tufail A, Bunce C, da Cruz L, Dowler J, Egan C, et al.A randomised, double-masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age-related macular degeneration: clinical trial design. Trials 2008;9:56.
5. Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, et al.Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ 2010;340:c2459.
6. Alexander SG, Blodi BA, Webster MKW, Elledge JA, Hiner CJ, Armstrong J, et al.Ranibizumab (Lucentis®) in subjects With predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science 2006;47:ARVO E-abstract 2207.
7. Barbazetto I, Saroj N, Shapiro H, Wong P, Freund KB. Dosing regimen and the frequency of macular hemorrhages in neovascular age-related macular degeneration treated with ranibizumab. Retina 2010;30(9):1376-85.
8. Barbazetto IA, Saroj N, Shapiro H, Wong P, Ho AC, Freund KB. Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology 2010;149(6):939-46.
9. Bressler NM, Boyer DS, Williams DF, Butler S, Francom SF, Brown B, et al.Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina 2012;32(9):1821-8.
10. Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J, Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration (ANCHOR) Research Group. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology 2009;127(1):13-21.
11. Bressler NM, Chang TS, Suñer IJ, Fine JT, Dolan CM, Ward J, et al.Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology 2010;117(4):747-56.
12. Bressler NM, Chang TS, Varma R, Suner I, Lee P, Dolan CM, et al.Driving ability reported by neovascular age-related macular degeneration patients after treatment with ranibizumab. Ophthalmology 2013;120(1):160-8.
13. Bressler NM, Dolan CM, Fine J, Marceau C, Chang TS. Vision-specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti-Angiogenesis (Part 2). Available at www.evrs.eu/2006-evrs-congress-cannes (accessed 13 March 2013).
14. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim R, et al.Ranibizumab versus verteporfin for neovascular age-related macular degeneration. New England Journal of Medicine 2006;355(14):1432-44.
15. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, et al.Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116(1):57-65.
16. Brown DM, Shapiro H, Schneider S. Subgroup analysis of first-year results of ANCHOR: a phase III, double-masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age-related macular degeneration. Investigative Ophthalmology and Visual Science 2006;47:ARVO E-abstract 2963.
17. Chang TS, Fine JT, Bressler N. Self-reported vision-specific quality of life at 1 year in patients with neovascular age-related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science 2006;47:ARVO E-abstract 5252.
18. Ciulla TA, Shapiro H, Schneider S. Ranibizumab (Lucentis®) for neovascular age-related macular degeneration (AMD): 1-year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science 2007;48:ARVO E-Abstract 4573.
19. Cunningham ET, Feiner L, Chung C, Tuomi L, Ehrlich JS. Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration. Ophthalmology 2011;118(12):2447-52.
20. Heier JS, Chung C, Schneider S. Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2-tear ANCHOR study of patients with neovascular age-related macular degeneration (AMD). Investigative Ophthalmology and Visual Science 2007;48:ARVO E-Abstract 2872.
21. Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, et al.Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. American Journal of Ophthalmology 2007;144(6):850-7.
22. Korobelnik JF. Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti-Angiogenesis (Part 1). Available at www.evrs.eu/2006-evrs-congress-cannes (accessed 13 March 2013).
23. Lanzetta P. Ranibizumab and patient-reported outcomes: VFQ-25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science 2008;49:ARVO E-abstract 5571.
24. Lanzetta P, MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti-Angiogenesis (Part 1). Available at www.evrs.eu/2006-evrs-congress-cannes (accessed 13 March 2013).
25. Loewenstein A, MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age-related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti-Angiogenesis (Part 1). Available at www.evrs.eu/2006-evrs-congress-cannes (accessed 13 March 2013).
26. McDonald HR, Schneider S, Sy JP. One-year results of ANCHOR: a phase III, multicenter, randomized, double-masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age-related macular degeneration. The Macula Society. 2006:114.
27. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: A multicenter cohort study (SEVEN-UP). Ophthalmology 2013;120(11):2292-9.
28. Rosenfeld PJ, Shapiro H, Shams N, Schneider S, Depperschmidt EE, MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science 2007;48:ARVO E-abstract 4576.
29. Rosenfeld PJ, Shapiro H, Tuomi L, Webster M, Elledge J, Blodi B. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology 2011;118(3):523-30.
30. Rosenfeld PJ, Shapiro H, Tuomi L, Webster M, Elledge J, Blodi B. Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age-related macular degeneration (AMD). Investigative Ophthalmology and Visual Science 2008;49:ARVO E-abstract 329.
31. Sadda SR, Shapiro H, Schneider S. Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age-related macular degeneration (AMD). Investigative Ophthalmology and Visual Science 2007;48:ARVO E-abstract 4561.
32. Sadda SR, Stoller G, Boyer DS, Blodi BA, Shapiro H, Ianchulev T. Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study. Retina 2010;30(9):1390-9.
33. Schwartz SG, Bressler N, Fine JT, Dolan CM, Yu EM, Ward JF, et al.Patient-reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science 2007;48:ARVO E-abstract 1822.
34. Sutter FK, Kurz-Levin MM. Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science 2008;49:ARVO E-abstract 2884.
35. Webster MK, Blodi BA, Elledge JA, Danis RP. Angiographic results of the ANCHOR study of ranibizumab in neovascular age-related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science 2007; Vol. 48:ARVO E-Abstract 4583.
36. Weinberg DV, Shapiro H, Ehrlich JS. Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: An individual patient data analysis of 2 phase 3 trials. Ophthalmology 2013;120(6):1278-82.
37. Win PH, Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J. Self-reported perception of driving function after ranibizumab therapy in patients with neovascular age-related macular degeneration (AMD). Investigative Ophthalmology and Visual Science 2008;49:ARVO E-abstract 5578.
38. Wolf S. Visual acuity gain with ranibizumab therapy: two-year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science 2008;49:ARVO E-abstract 2883.
39. Wolf S, Holz F G, Korobelnik J F, Lanzetta P, Mitchell P, Prünte C, et al.Outcomes following three-line vision loss during treatment of neovascular age-related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology 2011;95(12):1713-8.
40. Yang YC. Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age-related macular degeneration. Investigative Ophthalmology and Visual Science 2007;48:ARVO E-Abstract 4545.
41. Biswas P, Sengupta S, Choudhary R, Home S, Paul A, Sinha S. Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration. Indian Journal of Ophthalmology 2011;59(3):191-6.
42. Comparison of Age-related macular degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011).
43. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. New England Journal of Medicine 2011;364(20):1897-908.
44. Daniel E, Toth CA, Grunwald JE, Jaffe GJ, Martin DF, Fine SL, et al.Risk of scar in the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology 2014; Vol. 121, issue 3:656-66.
45. Grunwald JE, Daniel E, Huang J, Ying GS, Maguire MG, Toth CA, et al.Risk of geographic atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 2014;121(1):150-61.
46. Grunwald JE, Daniel E, Ying GS, Pistilli M, Maguire MG, Alexander J, et al.Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 2012;119(8):1634-41.
47. Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Callanan DG, et al.Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology 2013; Vol. 120, issue 3:593-9.
48. Jaffe GJ, Martin DF, Toth CA, Daniel E, Maguire MG, Ying GS, et al.Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2013;120(9):1860-70.
49. Maguire MG. Comparing treatments for age-related macular degeneration: safety, effectiveness and cost. LDI Issue Brief 2012; Vol. 17, issue 8:1-4.
50. Maguire MG, Daniel E, Shah AR, Grunwald JE, Hagstrom SA, Avery RL, et al.Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2013;120(10):2035-41.
51. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, et al.Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results. Ophthalmology 2012;119(7):1388-98.
52. Ying GS, Huang J, Maguire MG, Jaffe GJ, Grunwald JE, Toth C, et al.Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2013;120(1):122-9.
53. Kodjikian L, Souied EH, Mimoun G, Mauget-Faysse M, Behar-Cohen F, Decullier E, et al.Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: Results from the GEFAL noninferiority randomized trial. Ophthalmology 2013;120(11):2300-9.
54. A randomised controlled trial of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation. www.ivan-trial.co.uk/Default.aspx (accessed 4 April 2014).
55. Erratum: Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399-1411)). Ophthalmology 2012;119(8):1508.
56. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013;382(9900):1258-67.
57. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, et al.Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119(7):1399-411.
58. Lotery AJ, Gibson J, Cree AJ, Downes SM, Harding SP, Rogers CA, et al.Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN study. Ophthalmology 2013;120(12):2637-43.
59. Krebs I, Schmetterer L, Boltz A, Told R, Vécsei-Marlovits V, Egger S, et al.A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. British Journal of Ophthalmology 2013;97(3):266-71.
60. Barbazetto I, Saroj N, Shapiro H, Wong P, Freund KB. Dosing regimen and the frequency of macular hemorrhages in neovascular age-related macular degeneration treated with ranibizumab. Retina 2010;30(9):1376-85.
61. Barbazetto IA, Saroj N, Shapiro H, Wong P, Ho AC, Freund KB. Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology 2010;149(6):939-46.
62. Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR, MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114(2):246-52.
63. Bressler NM, Boyer DS, Williams DF, Butler S, Francom SF, Brown B, et al.Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina 2012;32(9):1821-8.
64. Bressler NM, Chang TS, Suñer IJ, Fine JT, Dolan CM, Ward J, et al.Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology 2010;117(4):747-56.
65. Bressler NM, Chang TS, Varma R, Suner I, Lee P, Dolan CM, et al.Driving ability reported by neovascular age-related macular degeneration patients after treatment with ranibizumab. Ophthalmology 2013;120(1):160-8.
66. Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J. Self-reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science 2007;48:ARVO E-Abstract 1830.
67. Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR, et al.Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology 2007;125(11):1460-9.
68. Chang TS, Fine JT, Alexander S, Bressler N. Ranibizumab (Lucentis®) self-reported vision specific quality of life through 12 months in age-related macular degeneration patients with minimally classic or occult-with-no-classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106.
69. Chang TS, Fine JT, Bressler N. Self-reported vision-specific quality of life at 1 year in patients with neovascular age-related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science 2006;47:ARVO E-abstract 5252.
70. Chang TS, Fine JT, Dolan CM, Marceau C, Bressler NM. Ranibizumab (Lucentis®) vision-specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti-Angiogenesis (Part 2). Available at www.evrs.eu/2006-evrs-congress-cannes (accessed 13 March 2013).
71. Ciulla TA, Shapiro H, Schneider S. Ranibizumab (Lucentis®) for neovascular age-related macular degeneration (AMD): 1-year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science 2007;48:ARVO E-abstract 4573.
72. Cunningham ET, Feiner L, Chung C, Tuomi L, Ehrlich JS. Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration. Ophthalmology 2011;118(12):2447-52.
73. Heier JS, Shapiro H, Singh AA. Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age-related macular degeneration: two-year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science 2006;47:ARVO E-abstract 2959.
74. Ho A, Shapiro H, Acharya N. Ranibizumab for neovascular age-related macular degeneration: one-year subanalysis of the MARINA study. The Macula Society. 2006:108.
75. Holekamp NM, Acharya N, Shapiro H. Two-year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194.
76. Hurley SF, Matthews JP, Guymer RH. Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration. Cost Effectiveness and Resource Allocation 2008;6:12.
77. Kaiser PK, Blodi BA, Shapiro H, Acharya NR, MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114(10):1868-75.
78. Kokame GT. Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age-related macular degeneration. The Macula Society. 2006:110.
79. Korobelnik JF. Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti-Angiogenesis (Part 1). Available at www.evrs.eu/2006-evrs-congress-cannes (accessed 13 March 2013).
80. Lanzetta P, MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti-Angiogenesis (Part 1). Available at www.evrs.eu/2006-evrs-congress-cannes (accessed 13 March 2013).
81. Loewenstein A, MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age-related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti-Angiogenesis (Part 1). Available at www.evrs.eu/2006-evrs-congress-cannes (accessed 13 March 2013).
82. Miller JW, Shapiro H, Acharya N. Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age-related macular degeneration: two-year safety results of the MARINA study. Investigative Ophthalmology and Visual Science 2006;47:ARVO E-abstract 3539.
83. Reichel E, Shapiro H, Acharya N. Subgroup analyses of two-year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194.
84. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: A multicenter cohort study (SEVEN-UP). Ophthalmology 2013;120(11):2292-9.
85. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al.Ranibizumab for neovascular age-related macular degeneration. New England Journal of Medicine 2006;355(14):1419-31.
86. Rosenfeld PJ, Shapiro H, Shams N, Schneider S, Depperschmidt EE, MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science 2007;48:ARVO E-abstract 4576.
87. Rosenfeld PJ, Shapiro H, Tuomi L, Webster M, Elledge J, Blodi B. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology 2011;118(3):523-30.
88. Rosenfeld PJ, Shapiro H, Tuomi L, Webster M, Elledge J, Blodi B. Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age-related macular degeneration (AMD). Investigative Ophthalmology and Visual Science 2008;49:ARVO E-abstract 329.
89. Schmidt-Erfurth U, Williams GA, MARINA Study Group. Two-year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti-Angiogenesis (Part 1). Available at www.evrs.eu/2006-evrs-congress-cannes (accessed 13 March 2013).
90. Suner IJ, Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J. Vision-related function after ranibizumab treatment by better- or worse-seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science 2007;48:ARVO E-Abstract 1808.
91. Sutter FK, Kurz-Levin MM. Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science 2008;49:ARVO E-abstract 2884.
92. Webster MK, Blodi BA, Glaeser Alexander S, Elledge KA, Hiner C, Hurtenbach CH, et al.Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science 2006;47:ARVO E-abstract 2206.
93. Weinberg DV, Shapiro H, Ehrlich JS. Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: An individual patient data analysis of 2 phase 3 trials. Ophthalmology 2013;120(6):1278-82.
94. Wolf S. Visual acuity gain with ranibizumab therapy: two-year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science 2008;49:ARVO E-abstract 2883.
95. Wolf S, Holz FG, Korobelnik JF, Lanzetta P, Mitchell P, Prünte C, et al.Outcomes following three-line vision loss during treatment of neovascular age-related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology 2011;95(12):1713-8.
96. Yu EB, Bressler NM, Fine JT, Ward JF, Dolan CM, Klesert T, et al.Relationship between patient-reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science 2007;48:ARVO E-abstract 1174.
97. Abraham P, Yue H, Shams N. PIER: Year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age-related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti-Angiogenesis (Part 1). Available at www.evrs.eu/2006-evrs-congress-cannes (accessed 13 March 2013).
98. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. American Journal of Ophthalmology 2010;150(3):315-24.
99. Barbazetto I, Saroj N, Shapiro H, Wong P, Freund KB. Dosing regimen and the frequency of macular hemorrhages in neovascular age-related macular degeneration treated with ranibizumab. Retina 2010;30(9):1376-85.
100. Benz MS, Brown DM, Shapiro H, Tuomi L. Ranibizumab for neovascular age-related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science 2008;49:ARVO E-abstract 347.
101. Bressler NM, Boyer DS, Williams DF, Butler S, Francom SF, Brown B, et al.Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina 2012;32(9):1821-8.
102. Brown DM, Chung CY, Tuomi L. Ranibizumab (Lucentis®) for neovascular age-related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78.
103. Brown DM, Tuomi L, Shapiro H, PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration. Retina 2013;33(1):23-34.
104. Brown DM, Yue H, Shams N. Ranibizumab (Lucentis®) in neovascular age-related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science 2007;48:ARVO E-Abstract 4540.
105. Cunningham ET, Feiner L, Chung C, Tuomi L, Ehrlich JS. Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration. Ophthalmology 2011;118(12):2447-52.
106. Ho AC, Shapiro H, Wilson L. Ranibizumab (Lucentis®) for neovascular age-related macular degeneration (AMD): two-year angiographic results of PIER study. The Macula Society. 2008:164.
107. Ho AC, Yue H, Wilson L. Ranibizumab in wet age-related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science 2008;49:ARVO E-abstract 368.
108. Kaiser PK, Yue H, Shams N. Subgroups analyses of one-year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195.
109. Lanzetta P. Ranibizumab and patient-reported outcomes: VFQ-25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science 2008;49:ARVO E-abstract 5571.
110. Michels M, Shapiro H, Wilson L. Ranibizumab (Lucentis®) for neovascular age-related macular degeneration (AMD): 2-year angiographic results of PIER study. Investigative Ophthalmology and Visual Science 2008;49:ARVO E-abstract 2882.
111. Mieler WF. PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti-Angiogenesis (Part 1). Available at www.evrs.eu/2006-evrs-congress-cannes (accessed 13 March 2013).
112. Regillo CD, Bressler NM, Fine JT, Dolan CM, Marceau C, Chang TS. Vision-specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. Available at www.evrs.eu/2006-evrs-congress-cannes/poster-session-amdanti-angiogenesis (accessed 13 March 2013).
113. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, et al.Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. American Journal of Ophthalmology 2008;145(2):239-48.
114. Regillo CD, Chung CY, Wilson L, PIER Study Group. Ranibizumab in neovascular age-related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166.
115. Wolf S. Visual acuity gain with ranibizumab therapy: two-year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science 2008;49:ARVO E-abstract 2883.
116. Michels SM, Weigert G, Geitzenauer W, Sacu S, Alina V, Schmidt-Erfurth U. Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age-related macular degeneration. Investigative Ophthalmology and Visual Science 2007;48:ARVO E-abstract 1820.
117. Prager F, Michels S, Sacu S, Weigert G, Dunavölgyi R, Geitzenauer W, et al.Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial. Investigative Ophthalmology and Visual Science 2008;49:ARVO E-abstract 1168.
118. Sacu S, Michels S, Prager F, Weigert G, Dunavoelgyi R, Geitzenauer W, et al.Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long-term results. Eye 2009;23(12):2223-7.
119. Weigert G, Michels S, Sacu S, Varga A, Prager F, Geitzenauer W, et al.Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology 2008;92(3):356-60.
120. Donahue SP, Recchia F, Sternberg P Jr. Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial. American Journal of Ophthalmology 2010;150(2):287.
121. Messori A, Fadda V, Trippoli S. Randomized study of bevacizumab vs ranibizumab for age-related macular degeneration: inappropriate conclusions. American Journal of Ophthalmology 2010;149(5):867.
122. Subramanian ML, Abedi G, Ness S, Ahmed E, Fenberg M, Daly MK, et al.Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. Eye 2010;24(11):1708-15.
123. Subramanian ML, Ness S, Abedi G, Ahmed E, Daly M, Feinberg E, et al.Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial. American Journal of Ophthalmology 2009;148(6):875-82.
124. Subramanian ML, Ness S, Abedi G, Ahmed E, Daly M, Feinberg E, et al.Reply. American Journal of Ophthalmology 2010;149(5):867.
125. Chakravarthy U. Efficacy and safety of pegaptanib in age-related macular degeneration: three-year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116.
126. D'Amico DF. Macugen® in neovascular age-related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261.
127. D'Amico DJ. VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science 2005;46:ARVO E-abstract 2309.
128. D'Amico DJ, Bird A C. VEGF Inhibition Study in Ocular Neovascularization-1 (VISION-1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science 2004;45:ARVO E-abstract 2363.
129. Eyetech Pharmaceuticals, Inc, Pfizer. Inc. Pegaptanib sodium injection in the treatment of neovascular age-related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4053b1.htm (accessed 20 December 2011).
130. FDA. Macugen® (pegaptanib sodium injection) for the treatment of neovascular age-related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4053b1.htm (accessed 20 December 2011).
131. Gragoudas ES. VEGF Inhibition Study in Ocular Neovascularization-1 (VISION-1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science 2004;45:ARVO E-abstract 2364.
132. Gragoudas ES, Adamis AP, Cunningham Jr ET, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. New England Journal of Medicine 2004;351(27):2805-16.
133. Jackson TL, Danis RP, Goldbaum M, Slakter JS, Shusterman EM, Oeshaughnessy DJ, et al.Retinal vascular abnormalities in neovascular age-related macular degeneration. Retina 2014;34(3):568-75.
134. Kuppermann BD. The V.I.S.I.O.N Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178.
135. Larsen M, Sander B, Villumsen JE, Haamann PH, la Cour M, Lund-Andersen H, et al.Treatment of neovascular age-related macular degeneration with intravitreal vascular endothelial growth factor inhibitor--secondary publication. Ugeskrift for Laeger 2005;167(35):3301-5.
136. Leys A, Zlateva G, Shah SN, Patel M. Quality of life in patients with age-related macular degeneration: results from the VISION study. Eye 2008;22(6):792-8.
137. Macugen AMD Study Group, Apte RS, Modi M, Masonson H, Patel M, Whitfield L, et al.Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology 2007;114(9):1702-12.
138. Marcus DM. Four-year safety of pegaptanib sodium in neovascular age-related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science 2008;49:ARVO E- abstract 5069.
139. Mieler W. Safety evaluation of second year treatment of age-related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science 2005;46:ARVO E-abstract 1380.
140. Mills E, Heels-Ansdell D, Kelly S, Guyatt G. A randomized trial of Pegaptanib sodium for age-related macular degeneration used an innovative design to explore disease-modifying effects. Journal of Clinical Epidemiology 2007;60(5):456-60.
141. Patel M, Mones J, Leys A, Zlateva G, Shah SN. Quality of life in patients with age-related macular degeneration: results from the VI.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. Available at www.evrs.eu/2006-evrs-congress-cannes/poster-session-amdanti-angiogenesis (accessed 13 March 2013).
142. Rakic JM, Blaise P, Foidart JM, Gragoudas ES, Adamis AP, Feinsod M. Pegaptanib and age-related macular degeneration. New England Journal of Medicine 2005;352(16):1720-1.
143. Singerman LI. Two-year systemic safety of pegaptanib in patients with neovascular age-related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120.
144. Singerman LJ, Masonson H, Patel M, Adamis AP, Buggage R, Cunningham E, et al.Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology 2008;92(12):1606-11.
145. Sjolie AK, Mortensen KK, Hansen MH. Antiangiogenesis therapy of age-related macular degeneration. Ugeskrift for Laeger 2005;167(35):3267.
146. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, Chakravarthy U, Adamis AP, Cunningham ET Jr, Goldbaum M, Guyer DR, et al.Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006; Vol. 113, issue 9:1508.
147. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET, et al.Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006;113(6):1001.
148. Zlateva G, Patel M, Shah SN. Quality of life in patients with age-related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science 2006;47:ARVO E-abstract 2152.
149. Bashshur ZF, Schakal A, Hamam RN, El Haibi CP, Jaafar R, Noureddin BN. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. Archives of Ophthalmology 2007;125(10):1357-61.
150. Schmid-Kubista KE, Krebs I, Gruenberger B, Schueller J, Binder S. Systemic bevacizumab therapy for exudative neovascular age-related macular degeneration (BEAT-AMD-Study). Investigative Ophthalmology and Visual Science 2008;49:ARVO E-abstract 304.
151. Schmid-Kubista KE, Krebs I, Gruenberger B, Zeiler F, Schueller J, Binder S. Systemic bevacizumab (Avastin®) therapy for exudative neovascular age-related macular degeneration. The BEAT-AMD-Study. British Journal of Ophthalmology 2009;93(7):914-9.
152. Bolz M, Pruente C, Benesch T, Ritter M, Deak G, Golbaz I, et al.The relevance of measuring central retinal thickness during intra-vitreal therapy with ranibizumab: analyzing a multi-center clinical trial. Investigative Ophthalmology and Visual Science 2008;49:ARVO E-abstract 5576.
153. Cohen SY, Bremond-Gignac D, Quentel G, Mimoun G, Citterio T, Bisot-Locard S, et al.Cost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology 2008;246(11):1527-34.
154. Costagliola C, Romano MR, Rinaldi M, dell'Omo R, Chiosi F, Menzione M, Semeraro F. Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. British Journal of Ophthalmology 2010;94(2):180-4.
155. Earnshaw SR, Moride Y, Rochon S. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada. Clinical Therapeutics 2007;29(9):2096-106.
156. Erdokur O, Tetikoglu M, Ozturk M, Elcioglu M. Results of comparison in use to alternative therapy methods for subfoveal choroidal neovascularization secondary to age-related macular degeneration. Retina-Vitreus 2009;17(4):245-50.
157. Tano Y. The safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration: 12-month results from the phase I/II EXTEND-I study. Investigative Ophthalmology and Visual Science 2008;49:ARVO E-abstract 272.
158. Tano Y, Ohji M, EXTEND-I Study Group. EXTEND-I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Acta Ophthalmologica 2010;88(3):309-16.
159. Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 2003;110(5):979-86.
160. Falkenstein IA, Cheng L, Morrison VL, Kozak I, Tammewar AM, Freeman WR. Standardized visual acuity results associated with primary versus secondary bevacizumab (Avastin®) treatment for choroidal neovascularization in age-related macular degeneration. Retina 2007;27(6):701-6.
161. Fletcher EC, Lade RJ, Adewoyin T, Chong NV. Computerized model of cost-utility analysis for treatment of age-related macular degeneration. Ophthalmology 2008;115(12):2192-8.
162. Antoszyk AN, Tuomi L, Chung CY, Singh A, FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. American Journal of Ophthalmology 2008;145(5):862-74.
163. Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumber MJ, Gentile RC, et al.Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS study. Archives of Ophthalmology 2006;124(11):1532-42.
164. Heier JS, FOCUS Study Group. Intravitreal ranibizumab with verteporfin photodynamic therapy for neovascular age-related macular degeneration: year one results. Program and abstracts of the American Society of Retina Specialists 23rd Annual Meeting; 2005 July 16-20; Montreal. 2005.
165. Hahn R, Sacu S, Michels S, Varga A, Weigert G, Geitzenauer W, et al.Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age-related macula degeneration. Der Ophthalmologe 2007;104(7):588-93.
166. Hatta Y, Ishikawa K, Nishihara H, Ozawa S, Ito Y, Terasaki H. Effect of photodynamic therapy alone or combined with posterior subtenon triamcinolone acetonide or intravitreal bevacizumab on choroidal hypofluorescence by indocyanine green angiography. Retina 2010;30(3):495-502.
167. Heier JS, Antoszyk AN, Pavan PR, Leff SR, Rosenfeld PJ, Ciulla TA, et al.Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006;113(4):642. e1-4.
168. Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, Giraldez J. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration. Clinical Therapeutics 2008;30(12):2436-51.
169. Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, Giraldez J. Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration. Investigative Ophthalmology and Visual Science 2010;248(4):467-76.
170. Javitt JC, Zlateva GP, Earnshaw SR, Pleil AM, Graham CN, Brogan AJ, et al.Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity. Value in Health 2008;11(4):563-74.
171. Lai TY, Liu DT, Chan KP, Luk FO, Pang CP, Lam DS. Visual outcomes and growth factor changes of two dosages of intravitreal bevacizumab for neovascular age-related macular degeneration: a randomized, controlled trial. Retina 2009;29(9):1218-26.
172. Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007;114(6):1179-85.
173. Fang K, Tian J, Qing X, Li S, Hou J, Li J, et al.Predictors of visual response to intravitreal bevacizumab for treatment of neovascular age-related macular degeneration. Journal of Ophthalmology 2013;2013:676049.
174. Li X, Hu Y, Sun X, Zhang J, Zhang M, Neovascular Age-Related Macular Degeneration Treatment Trial Using Bevacizumab (NATTB). Bevacizumab for neovascular age-related macular degeneration in China. Ophthalmology 2012;119(10):2087-93.
175. Li J, Zhang H, Sun P, Gu F, Liu ZL. Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients. International Journal of Ophthalmology 2013;6(2):169-73.
176. Matthe E, Sandner D. Monotherapy of exudative age-related macular degeneration with ranibizumab in patients at cardiovascular risk. Advantages of ranibizumab compared to a combination with pegaptanib. Der Ophthalmologe 2011;108(4):337-41.
177. Pulido JS, Anderson Jr, WB, Flynn JT, Lichter PR, Sanders D. Multicenter prospective, randomized, double-masked, placebo-controlled study of rheopheresis to treat neovascular age-related macular degeneration: Interim analysis. Transactions of the American Ophthalmological Society 2002;100:85-107.
178. Pulido JS, Sanders D, Klingel R. Rheopheresis for age-related macular degeneration: clinical results and putative mechanism of action. Canadian Journal of Ophthalmology 2005;40(3):332-40.
179. Modarres M, Naseripour M, Falavarjani KG, Nikeghbali A, Hashemi M, Parvaresh MM. Intravitreal injection of 2.5 mg versus 1.25 mg bevacizumab (Avastin®) for treatment of CNV associated with AMD. Retina 2009;29(3):319-24.
180. Neubauer AS, Holz FG, Schrader W, Back EI, Kuhn T, Hirneiss C, et al.Cost-utility analysis of ranibizumab (Lucentis®) in neovascular macular degeneration. Klinische Monatsblatter fur Augenheilkunde 2007; Vol. 224, issue 9:727-32.
181. Nguyen QD, Shah SM, Hafiz G, Quinlan E, Sung J, Chu K, et al.A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006;113(9):1522.
182. Nowak MS, Jurowski P, Grzybowski A, Goś R, Pastuszka M, Kapica A, et al.A prospective study on different methods for the treatment of choroidal neovascularization. The efficacy of verteporfin photodynamic therapy, intravitreal bevacizumab and transpupillary thermotherapy in patients with neovascular age-related macular degeneration. Medical Science Monitor 2012;18(6):CR374-80.
183. Parodi MB, Cascavilla M, Papayannis A, Kontadakis DS, Bandello F, Iacono P. Intravitreal bevacizumab in advanced-stage neovascular age-related macular degeneration with visual acuity lower than 20/200. Archives of Ophthalmology 2012;130(7):934-5.
184. Chakravarthy U, Staurenghi G, Kwok K, Tressler CS, Buggage R, PERSPECTIVES Study Group. Treating early choroidal neovascularisation with pegaptanib sodium in patients with neovascular age-related macular degeneration: findings of the PERSPECTIVES study. British Journal of Ophthalmology 2012;96(10):1351-4.
185. Raftery J, Clegg A, Jones J, Tan SC, Lotery A. Ranibizumab (Lucentis®) versus bevacizumab (Avastin®): modelling cost effectiveness. British Journal of Ophthalmology 2007;91(9):1244-6.
186. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009;116(9):1731-9.
187. Reichel E, Francom S, Rubio R. Ranibizumab (Lucentis®) safety in previously treated and newly diagnosed patients with neovascular age-related macular degeneration (AMD): the SAILOR study. The Macula Society. 2008:168.
188. Schmid-Kubista KE, Krebs I, Ansari-Shahrezaei S, Haas P, Hagen S, Binder S. Comparing treatment of neovascular age-related macular degeneration with sequential intravitreal Avastin and Macugen versus intravitreal mono-therapy-a pilot study. Current Eye Research 2011;36(10):958-63.
189. Slakter JS, DENALI Study Group. Combination therapy with verteporfin PDT and ranibizumab for subfoveal choroidal neovascularization due to AMD. Investigative Ophthalmology and Visual Science 2007;48:E-Abstract 1817.
190. Suñer IJ, Kokame GT, Yu E, Ward J, Dolan C, Bressler NM. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials. Investigative Ophthalmology and Visual Science 2009;50(8):3629-35.
191. Tano Y, Pegaptanib Sodium Multi-center Study Group. Pegaptanib sodium one-year treatment study for neovascular age-related macular degeneration. Nippon Ganka Gakkai Zasshi 2008;112(7):590-600.
192. Vallance JH, Johnson B, Majid MA, Banerjee S, Mandal K, Bailey CC. A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. Eye 2010;24(10):1561-7.
193. Mieler WF, The VERITAS trial. VERITAS - The rationale and design of a combination therapy trial for wet AMD. Investigative Ophthalmology & Visual Science 2006;47:E-Abstract 5232.
194. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, et al.Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 2014;121(1):193-201.
195. Wolowacz SE, Roskell N, Kelly S, Maciver FM, Brand CS. Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK. Pharmacoeconomics 2007;25(10):863-79.
196. Zehetner C, Kirchmair R, Huber S, Kralinger MT, Kieselbach GF. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. British Journal of Ophthalmology 2013;97(4):454-9.
197. NCT00087763. A phase II prospective, randomized, double-masked, sham-controlled, dose-ranging, multi-center trial to assess the effect of pegaptanib sodium on foveal thickening in patients with exudative subfoveal age-related macular degeneration (AMD). clinicaltrials.gov/show/NCT00087763 (accessed 14 August 2013).
198. NCT00531336. Comparison of combined therapy of intravitreal injection of Avastin and Macugen versus mono-therapy. The MAAM Study - a pilot study. clinicaltrials.gov/show/NCT00531336 (accessed 6 August 2013).
199. NCT00559715. Prevention of vision loss in patients with age-related macular degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab (VIBERA). clinicaltrials.gov/show/NCT00559715 (accessed 14 August 2013).
200. NCT01127360. Lucentis compared to Avastin study. A randomized, double blind, prospective multicenter study comparing the effect of intravitreal injection of Bevacizumab (Avastin) to Ranibizumab (Lucentis) when given to patients with exudative (wet) age-related macular degeneration. clinicaltrials.gov/show/NCT01127360 (accessed 11 January 2013).
201. NCT01319188. Ranibizumab for age-related macular degeneration and the risk of arterial thromboembolic events (RATE). clinicaltrials.gov/show/NCT01319188 (accessed 17 May 2013).
202. NCT02036723. Multicentre double blind randomized clinical study evaluating the efficacy and safety of BCD-021 (CJSC BIOCAD, Russia) and Lucentis® (Novartis Pharmaceuticals Canada Inc.) in patients with neovascular wet age-related macular degeneration. clinicaltrials.gov/show/NCT02036723 (accessed 4 April 2014).
203. Comparison of bevacizumab (Avastin) and ranibizumab (Lucentis) in exudative age-related macular degeneration. www.trialregister.nl/trialreg/admin/rctview.asp?TC=1704 (accessed 17 May 2013).
204. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al.Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New England Journal of Medicine 1994;331(22):1480-7.
205. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology 2001;119(10):1414-36.
206. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 2013;309(19):2005-15.
207. Boekhoorn SS, Vingerling JR, Witteman JCM, Hofman A, de Jong PT. C-reactive protein level and risk of aging macula disorder: The Rotterdam Study. Archives of Ophthalmology 2007;125(10):1396-401.
208. Bourne RR, Jonas JB, Flaxman SR, Keeffe J, Leasher J, Naidoo K, et al.Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990-2010. British Journal of Ophthalmology 2014;98(5):629-38.
209. Brown MM, Brown GC, Brown HC, Peet J. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. Ophthalmology 2008;115(6):1039-45.
210. Bunce C, Wormald R. Leading causes of certification for blindness and partial sight in England & Wales. BMC Public Health 2006;6:58.
211. Carneiro AM, Mendonca LS, Falcao MS, Fonseca SL, Brandao EM, Falcao-Reis FM. Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting. Clinical Ophthalmology 2012;6:1149-57.
212. Centers for Medicare and Medicaid Services. Billing and coding information regarding uses, including off-label uses, of bevacizumab and ranibizumab, for the treatment of ophthalmological diseases. Document ID A49034. www.cms.gov/medicare-coverage-database (accessed 9 April 2014).
213. Cohen D. Roche and Novartis colluded over wet AMD drugs, says Italian regulator. BMJ 2014;348:g2006.
214. Congdon N, O'Colmain B, Klaver CC, Klein R, Muñoz B, Friedman DS, et al.Causes and prevalence of visual impairment among adults in the United States. Archives of Ophthalmology 2004;122(4):477-85.
215. de Juan E, Laganovska G, Loewenstein A, Alster Y, Erickson S. First in-human results of a refillable drug delivery implant providing sustained release of ranibizumab in patients with neovascular AMD. Macula Society. 2013:136-7.
216. Deangelis MM, Ji F, Kim IK, Adams S, Capone A Jr, Ott J, et al.Cigarette smoking, CFH, APOE, ELOVL4, and risk of neovascular age-related macular degeneration. Archives of Ophthalmology 2007;125(1):49-54.
217. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
218. Eyetech Pharmaceuticals, Inc, Pfizer. Inc. Pegaptanib sodium injection in the treatment of neovascular age-related macular degeneration; and FDA. Macugen® (pegaptanib sodium injection) for the treatment of neovascular age-related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4053b1.htm (accessed 20 December 2011).
219. Eyetech Pharmaceuticals, Inc, Pfizer. Inc. Pegaptanib sodium injection in the treatment of neovascular age-related macular degeneration; and FDA. Macugen® (pegaptanib sodium injection) for the treatment of neovascular age-related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4053b1.htm (accessed 20 December 2011).
220. Friedman DS, O'Colmain BJ, Muñoz B, Tomany SC, McCarty C, de Jong PT, et al.Prevalence of age-related macular degeneration in the United States. Archives of Ophthalmology 2004;122(4):564-72.
221. Ghafour IM, Allan D, Foulds WS. Common causes of blindness and visual handicap in the west of Scotland. British Journal of Ophthalmology 1983;67(4):209-13.
222. Gillies MC, Walton RJ, Arnold JJ, McAllister IL, Simpson JM, Hunyor AP, et al.Comparison of outcomes from a phase 3 study of age-related macular degeneration with a matched, observational cohort. Ophthalmology 2014;121(3):676-81.
223. Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130-6.
224. Gragoudas ES, Adamis AP, Cunningham, Jr. ET, Feinsod M, Guyer DR, the VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. New England Journal of Medicine 2004;351(27):2805-16.
225. Haddad S, Chen CA, Santangelo SL, Seddon JM. The genetics of age-related macular degeneration: A review of progress to date. Survey of Ophthalmology 2006;51(4):316-63.
226. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
227. Holz FG, Bandello F, Gillies M, Mitchell P, Osborne A, Sheidow T, et al.Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme. British Journal of Ophthalmology 2013;97(9):1161-7.
228. Hyman L. Epidemiology of eye disease in the elderly. Eye 1987;1(Pt 2):330-41.
229. Ip MS, Scott IU, Brown GC, Brown MM, Ho AC, Huang SS, et al.Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology 2008;115(10):1837-46.
230. Klein R, Knudtson MD, Cruickshanks KJ, Klein BE. Further observations on the association between smoking and the long-term incidence and progression of age-related macular degeneration. Archives of Ophthalmology 2008;126(1):115-21.
231. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Investigative Ophthalmology & Visual Science 1996;37(9):1929-34.
232. Leibowitz HM, Krueger DE, Maunder LR, Milton RC, Kini MM, Kahn HA, et al.The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Survey of Ophthalmology 1980;24(Suppl):335-610.
233. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Investigative Ophthalmology and Visual Science 1996;37(5):855-68.
234. Mitchell P, Wang JJ, Smith W, Leeder SR. Smoking and the 5-year incidence of age-related maculopathy: the Blue Mountains Eye Study. Archives Ophthalmology 2002;120(10):1357-63.
235. Mitchell P. A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab. Current Medical Research and Opinion 2011;27(7):1465-75.
236. Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, et al.Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD011230]
237. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy Five-year results from randomized clinical trials Macular Photocoagulation Study Group. Archives of Ophthalmology 1991;109(8):1109-14.
238. Owen CG, Fletcher AE, Donoghue M, Rudnicka AR. How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom?. British Journal of Ophthalmology 2003;87(3):312-7.
239. Rasmussen A, Sander B. Long-term longitudinal study of patients treated with ranibizumab for neovascular age-related macular degeneration. Current Opinion in Ophthalmology 2014;25(3):158-63.
240. Review Manager (RevMan) [Computer program]. Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
241. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 2013;120(11):2292-9.
242. Schaumberg DA, Hankinson SE, Guo Q, Rimm E, Hunter DJ. A prospective study of 2 major age-related macular degeneration susceptibility alleles and interactions with modifiable risk factors. Archives of Ophthalmology 2007;125(1):55-62.
243. Schmucker C, Ehlken C, Hansen LL, Antes G, Agostini HT, Lelgemann M. Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review. Current Opinion in Ophthalmology 2010;21(3):218-26.
244. Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M, et al.A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. PloS One 2012;7(8):e42701.
245. Seddon JM, George S, Rosner B, Klein ML. CFH gene variant, Y402H, and smoking, body mass index, environmental associations with advanced age-related macular degeneration. Human Heredity 2006;61(3):157-65.
246. Smith W, Mitchell P, Leeder SR. Smoking and age-related maculopathy. The Blue Mountains Eye Study. Archives of Ophthalmology 1996;114(12):1518-23.
247. Submacular Surgery Trials Research Group, Solomon SD, Jefferys JL, Hawkins BS, Bressler NM. Incident choroidal neovascularization in fellow eyes of patients with unilateral subfoveal choroidal neovascularization secondary to age-related macular degeneration: SST report No. 20 from the Submacular Surgery Trials Research Group. Archives of Ophthalmology 2007;125(10):1323-30.
248. Stein JD, Newman-Casey PA, Mrinalini T, Lee PP, Hutton DW. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration. Ophthalmology 2014;121(4):936-45.
249. Tielsch JA. Vision problems in the US: a report on blindness and vision impairment in adults age 40 and older. Prevent Blindness. Illinois: Schaumberg, 1994.
250. Ting TD, Oh M, Cox TA, Meyer CH, Toth CA. Decreased visual acuity associated with cystoid macular edema in neovascular age-related macular degeneration. Archives of Ophthalmology 2002;120(6):731-7.
251. Van Kerckhoven W, Lafaut B, Follens I, De Laey JJ. Features of age-related macular degeneration on optical coherence tomography. Bulletin de la Societe Belge d' Ophtalmologie 2001;281:75-84.
252. Virgili G, Bini A. Laser photocoagulation for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD004763.pub2]
253. Wormald R, Evans J, Smeeth L, Henshaw K. Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD002030.pub2]
254. Krzystolik MG, Woodcome HA, Reddy U. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2005, Issue 1. [DOI: 10.1002/14651858.CD005139]
255. Vedula SS, Krzystolik M. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD005139.pub2]